首页> 外文期刊>American journal of therapeutics >Use of octreotide in the treatment of refractory orthostatic intolerance.
【24h】

Use of octreotide in the treatment of refractory orthostatic intolerance.

机译:使用奥曲肽治疗难治性直立性不耐症。

获取原文
获取原文并翻译 | 示例
           

摘要

There have been reports on the use of octreotide in patients with orthostatic hypotension, postural tachycardia syndrome, and orthostatic syncope. However, there are little if any data on the use of octreotide in patients who have failed multiple other medications. This study was a retrospective chart analysis and was approved by our Institutional Review Board. A total of 12 patients were identified for inclusion in this study. The diagnosis of orthostatic intolerance was based on patient history, physical examination, and response to Head Up Tilt Table testing. These patients had failed multiple medications and were ultimately treated with octreotide. In a retrospective chart review, we collected data, including demographic information, presenting symptoms, laboratory data, tilt-table response, standing heart rate, standing blood pressure before and after treatment (wherever available), and treatment outcomes. Twelve patients aged 33 +/- 18 years, eight (66.7%) females, were found to have symptoms of refractory orthostatic intolerance and failed multiple regimens of medication and were ultimately treated with octreotide administration. Five patients (41.7%) had demonstrated a postural tachycardia syndrome pattern, five (41.7%) a neurocardiogenic, and two (16.6%) a dysautonomic response on a Head Up Tilt Table. Symptoms of syncope and orthostatic palpitations improved in six (50%) of the patients. Standing heart rate was significantly reduced after octreotide administration (80 +/- 8 versus 108 +/- 13; P < 0.05). The standing systolic blood pressure was increased after octreotide administration (107 +/- 26 versus 116 +/- 22). Three patients (25%) reported complete elimination of syncope, whereas another three had reduction in the frequency of their syncope. However, symptoms of fatigue improved only in two (29%) of the seven patients. Octreotide may improve symptoms in some patients with refractory orthostatic intolerance.
机译:有报道称奥曲肽在体位性低血压,体位性心动过速综合征和体位性晕厥患者中使用。但是,几乎没有关于使用多种其他药物治疗失败的患者使用奥曲肽的数据。这项研究是一项回顾性图表分析,并得到了我们机构审查委员会的批准。总共确定了12名患者纳入本研究。体位不耐受的诊断基于患者的病史,体格检查以及对Head Up Tilt Table测试的反应。这些患者多次用药失败,最终接受了奥曲肽治疗。在回顾性图表审查中,我们收集了数据,包括人口统计学信息,表现出的症状,实验室数据,倾斜表反应,站立心率,治疗前后的站立血压(如有)以及治疗结果。十二名年龄在33 +/- 18岁的患者,八名(66.7%)女性,具有顽固的体位性耐受不良的症状,并且多次药物治疗均无效,最终接受了奥曲肽治疗。在Head Up Tilt Table上,五名患者(41.7%)表现出姿势性心动过速综合征模式,五名患者(41.7%)表现为神经源性,二名患者(16.6%)表现出自主神经功能减退。六名(50%)患者的晕厥和体位性心pit症状得到改善。使用奥曲肽后,站立时的心率显着降低(80 +/- 8对108 +/- 13; P <0.05)。服用奥曲肽后站立的收缩期血压升高(107 +/- 26对116 +/- 22)。三名患者(25%)报告完全消除了晕厥,而另外三名患者的晕厥发生率降低。但是,疲劳症状仅在七名患者中的两名(29%)得到改善。奥曲肽可改善部分顽固性体位不耐症患者的症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号